Enveda Biosciences fetches $51m Series A

Enveda Biosciences, a biotechnology company, has raised $51 million in Series A funding.

Enveda Biosciences, a biotechnology company, has raised $51 million in Series A funding. Lux Capital led the round with participation from other backers that included Two Sigma Ventures, Hummingbird VC, Catalio Capital, Lifeforce Capital, True Ventures, Wireframe Ventures and Village Global.

Source: Press Release